Nov 9 (Reuters) - Immutep Ltd IMM.AX :
* IMMUTEP'S PHASE II TACTI-002 STUDY REPORTS ENCOURAGING DATA AT SITC
* IMMUTEP LTD - OVERALL RESPONSE RATES IN 1(ST) LINE NSCLC AND 2(ND) LINE HNSCC CONTINUE TO BE VERY FAVOURABLE
* IMMUTEP LTD - ENCOURAGING EFFICACY FOR LOW PD-L1 EXPRESSING PATIENTS WHO DO NOT TYPICALLY RESPOND TO IMMUNE CHECKPOINT (PD-L1) THERAPY